STAAR Surgical to Report Third Quarter Results on November 2, 2022

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA) announced it will release its third-quarter financial results on November 2, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern to discuss the results and operational progress. Investors can access the call by dialing 844-200-6205 for domestic calls. The company, a leader in implantable lenses for ophthalmic surgery, has sold over 2 million ICLs globally. It operates facilities in California and Switzerland, emphasizing innovation in visual freedom solutions.

Positive

• Company has sold over 2 million Implantable Collamer Lenses (ICLs), indicating significant market penetration.
• Upcoming third-quarter earnings release on November 2, 2022, may provide insight into financial performance.

Negative

• None.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended September 30, 2022 on Wednesday, November 2, 2022 after the market close.

STAAR will host a conference call and webcast on Wednesday, November 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 976076), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Replay Code 710361) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 866-813-9403 for domestic callers and 929-458-6194 for international callers. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005015/en/

Investors & Media

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Source: STAAR Surgical Company

FAQ

When will STAAR Surgical announce its third-quarter earnings for 2022?

STAAR Surgical will announce its third-quarter earnings on November 2, 2022, after market close.

How can I listen to the STAAR Surgical financial results conference call?

You can listen to the STAAR Surgical conference call by dialing 844-200-6205 for domestic calls or 929-526-1599 for international calls.

What significant product has STAAR Surgical sold?

STAAR Surgical has sold over 2 million Implantable Collamer Lenses (ICLs), primarily the EVO Visian ICL™ product line.

Where does STAAR Surgical operate its manufacturing facilities?

STAAR Surgical operates manufacturing and packaging facilities in Lake Forest, Aliso Viejo, and Monrovia, California, as well as Nidau in Switzerland.